| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1881f4d96f9c47ca316b250d4ec42ea7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29f19d6af4747809145497ddcdf91bde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2abada4b6ae86566f16a48b50403ac5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05bd121ac26a84a5293d24697e083ace
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_400d2a9af8a713cf5cf5fe7ebd7554ea |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 |
| filingDate |
2009-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b9f909b1cd2765075acb21954f25e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f91cabbb8930c234dd2825ee82c29b99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb11d45bc2e752363fce3516b705f5e4 |
| publicationDate |
2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011075912-A1 |
| titleOfInvention |
Pharmaceutical composition for treating parkinson's disease and preparation method thereof |
| abstract |
A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011366717-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I419685-B |
| priorityDate |
2009-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |